Odiparcil is primarily investigated for its potential therapeutic applications in the treatment of thrombotic disorders. It functions as a modulator of glycosaminoglycan biosynthesis, which plays a critical role in regulating blood coagulation. By influencing the production of heparan sulfate and dermatan sulfate, it helps to maintain a balance between pro-coagulant and anti-coagulant activities, reducing the risk of abnormal clot formation. This makes it a promising candidate for preventing and treating conditions such as deep vein thrombosis, pulmonary embolism, and stroke. Additionally, its unique mechanism of action offers potential advantages over traditional anticoagulants, such as reduced bleeding risks, making it an attractive option for long-term therapy in patients with chronic thrombotic conditions. Research is ongoing to further explore its efficacy and safety in clinical settings.